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Abstract Neonatal fungal infections are associated with
substantial mortality and morbidity. Although prophylactic
use of several antifungals has been proposed, this practice
remains controversial. In order to evaluate the use of
fluconazole prophylaxis in European NICUs, we conducted
a cross-sectional survey by means of a structured question-
naire that was sent to European level II and III neonatal
intensive care units, over a 9-month period, as part of a
neonatal research FP7 European project. A total of 193
questionnaires from 28 countries were analysed. Use of
antifungal prophylaxis was reported by 55% of the respond-
ers, and the most frequently used antifungal agent was
fluconazole (92%). Main indications for prophylaxis were
low gestational age (<28 weeks) and birth weight (<1,000 g).
A dose of 3 mg/kg was used in 66% of NICUs using
fluconazole, with an administration interval of 72 h in 52% of
them. All responders acknowledged the need for additional
trialsontheefficacyofprophylacticfluconazole.Non-usersof
fluconazole prophylaxis were more likely to be influenced by
the local incidence of candidiasis, the risk of increasing
antifungal resistance and the absence of specific recommen-
dations by paediatric societies. Conclusions: Major concerns
about the use of fluconazole prophylaxis include its efficacy,
the risk of emergence of resistant species and the absence of
clear consensus to support routine use. Future studies that
address these issues will contribute to a more rational use of
fluconazole prophylaxis.
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IFIs Invasive fungal infections
VLBW Very low birth weight
ELBW Extremely low birth weight infants
NICUs Neonatal intensive care units
RCT Randomized controlled trial
GA Gestational age
TINN Treat infections in neonates
Introduction
Neonatal fungal infections, mainly due to Candida spp., are
often associated with substantial mortality and morbidity.
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DOI 10.1007/s00431-011-1565-8Major risk factors include low gestational age and very
low birth weight (VLBW, <1,500 g), use of steroids and
broad-spectrum antibiotics, prolonged presence of a
central venous catheter and use of parenteral nutrition
[13]. Estimated incidence of invasive fungal infections
(IFIs) is 2% in VLBW neonates and 3% to more than 23%
in extremely low birth weight (ELBW, <1,000 g) neonates.
Also, Candida-associated mortality rates are high, espe-
cially in ELBW infants, 73% of which either do not
survive or survive with neurodevelopmental impairment
[3]. In addition, the real burden of neonatal IFIs is
probably underestimated because of diagnostic limitations
due to their subtle clinical presentation, frequent labora-
tory difficulties in identifying the pathogen and absence of
a consensus definition for IFIs [14].
Given the severity of these infections, the prophylactic
use of several antifungal agents has been proposed.
Successful results concerning the azole agent fluconazole
have prompted certain neonatal intensive care units
(NICUs) to adopt its use in prophylaxis mainly in the
population of extremely premature infants. Yet, this medical
practice remains controversial [20]. In a US survey
conducted in 2004, only 34% of the participating neo-
natologists reported the use of antifungal prophylaxis [5].
From that survey to date, eight retrospective studies [1, 4,
10, 11, 15, 22, 26, 29], two prospective randomized
controlled trials (RCTs) [16, 21] and a Cochrane meta-
analysis [7] have demonstrated the efficacy of fluconazole
prophylaxis. Hence, the Infectious Disease Society of
America 2009 guidelines recommend fluconazole prophy-
laxis “for premature infants and infants with ELBW in
nurseries that have a high incidence of invasive candidia-
sis” [23]. In this context, we aimed to evaluate the use of
fluconazole for the prevention of IFIs and the factors that
influence this practice in European NICUs.
Materials and methods
Selection of study participants
This survey was part of a wider study conducted by the FP7
European project Treat Infections in Neonates (TINN)
research network. This network was established by the
European Commission in 2007 to evaluate the use of two
off-patent medicines in neonates: ciprofloxacin and fluco-
nazole [9]. This collaborative project has brought together a
group of neonatal health experts from seven countries. To
conduct the survey, given the absence of an exhaustive list
of European NICUs, the TINN experts were asked to
identify units located in their respective countries and in
other European countries. Also, paediatric European net-
works and national societies were contacted to provide
additional information on existing NICUs. Between
December 2009 and May 2010, a first invitation to
participate in the online survey was emailed to the heads of
all identified NICUs. Then, a second email was sent in June
2010 to urge clinicians to either participate or complete
provided information. The invitation to participate mentioned
that the study involved the use of an antimicrobial agent
without specifying the drug. Also, neonatologists initially
contacted were urged to pass the invitation on to other heads
of NICUs.
As the characteristics of NICUs differ widely in Europe
[27], we analysed data provided by level II and III neonatal
care units as defined in a previous publication [25]. Also,
only one completed questionnaire per unit was analysed.
Survey
The survey was conducted by means of a questionnaire
that was directly completed by neonatologists online. This
questionnaire had been constructed and pre-tested by
TINN experts. The following information were assessed:
characteristics of the unit (level of care, total number of
neonatal beds, average annual admissions of neonates and
those of newborns less than 32 weeks' gestational age
(GA), estimated monthly rate of sepsis, prevalence of
fungal infections) and use or not of fluconazole prophy-
laxis. We considered a prevalence of fungal infections of
less than 1% to be low, based on previous published data
[13, 23]. For units prescribing prophylactic fluconazole,
clinical indications, drug doses and dosing schedules,
reasons for discontinuation and the nature of the agent
prescribed for treatment of confirmed fungal infection
were noted. Information on the following items—number
of NICU beds, average annual admission of neonates,
estimated prevalence of fungal infections, use or not of
prophylactic fluconazole—were compulsory for inclusion
in the survey analysis.
Each unit's rationale regarding fluconazole prophylaxis
was evaluated by the responses given to nine items
addressing different factors that may have influenced this
practice. Responses were measured on a 5-point Likert
scale (1, least important; 5, most important) and were
further dichotomized: responses ≤3 were considered as less
important and those ≥4 as very important. We integrated the
same items as in the 2004 US survey [5].
Statistical analysis
Descriptive data included absolute numbers (percentages)
for categorical variables and medians [1st–3rd quartile] for
continuous variables. To compare proportions, we used a
chi-square or Fisher's exact test and the Wilcoxon nonpara-
metric test to compare medians. All differences were
440 Eur J Pediatr (2012) 171:439–445significant at a p<0.05 level. Statistical analyses were
performed using SAS version 9.2 software.
Results
By September 2010, 327 neonatologists had accessed the
online survey, and 226 had inputted any data. Further, 33
questionnaires were excluded because they were duplicates
(n=22), compulsory information was missing (n=4) and
they were provided by non-European countries (n=5) orby
level I NICUS (n=2). Thus, a total of 193 questionnaires
from 193 units located in 28 countries were analysed; those
with the greatest number of NICUs that joined the survey
were Italy, the UK and France.
Characteristics of participating NICUs
Most NICUS were level III units (167 of 193, 86.5%) with
a median number of neonatal beds of 14 (8–22) and a mean
of more than 120 admissions of newborns (160 of 193,
83%) per year. The majority reported annual admissions of
preterm neonates of either 50 to 100 (77 of 193, 40%) or
100 to 200 (58 of 193, 30%). In 72% (139 of 193) of the
units, the monthly rate of bacterial sepsis was estimated
between 1% and 10%. The reported prevalence of fungal
infections was less than 1% in 125 units (65%), 1% to 5%
in 56 (29%) and 5% to 15% in 12 (6%) NICUs.
Use of fluconazole prophylaxis
One hundred and seven NICUs (55%) reported use of
antifungal prophylaxis. Of those, 75% (80 of 107) stated the
presence of a written protocol regarding routine antifungal
prophylaxis againstonly 26% (22 of86) oftheunitswhichdid
not use prophylaxis (p<0.0001). There were no other
statistically significant differences concerning the unit char-
acteristics described above. In particular, no difference was
found in the prevalence of fungal infections between users
and non-users of antifungal prophylaxis (prevalence <1%, 65
of 107 (61%) and 60 of 86 (70%), respectively; p=0.19).
Fluconazole was the most frequently used prophylactic
agent (99 of 107, 92%). Nystatin or miconazole (n=3;
agents not stated, n=5) was also prescribed. Details on the
indications to initiate fluconazole prophylaxis are given in
Table 1. Main indications for prophylaxis were a low GA
and weight at birth, and the most commonly reported cut-
offs were GA less than 28 weeks and birth weight less than
1,000 g. Almost half of the units initiate prophylaxis upon
positive fungal colonization; however, routine surveillance
cultures are performed by 58% (29 of 50) of these units,
and the remaining determine colonization status on cultures
motivated by clinical features (21 of 50, 42%).
Fluconazole was more often given intravenously (81%)
than orally (19%). A mean dose of 3 mg/kg was used in
66% of NICUs (6 mg/kg, 23%; other, 6%; missing, 5%),
with an administration interval of 72 h in 52% of them
( 4 8h ,2 2 % ;2 4h ,1 0 % ;o t h e r ,1 1 % ;m i s s i n g ,5 % ) .
Antifungal prophylaxis was discontinued after a predeter-
mined duration (range, 10 to 45 days) in 38% of the units,
when the intravenous route was no longer available in 35%
and when an appropriate corrected GA (range, 28–
33 weeks) or target weight (range, 1,000 to 2,000 g) was
reached in 9% and 6% of NICUS, respectively. Finally,
57% of the NICUs that use fluconazole prophylaxis
reported the administration of amphotericin B for the
treatment of a confirmed fungal infection. In the same
clinical context, fluconazole was prescribed in 23% of these
NICUs, flucytozine and caspofungin in 5% each and
micafungin in 1% (missing data, 9%).
Rationale for fluconazole prophylaxis
Overall, the items that were considered as most influential
on the decision to use or not to use fluconazole prophylaxis
were the NICU's incidence of candidiasis, the risk of
increasing drug resistance related to its widespread use and
the need for additional efficacy studies. Details are given in
Table 2.
However, differences were observed between NICUs
that used prophylactic fluconazole and those that did not
use prophylaxis. Neonatologists who did not prescribe
routine prophylaxis were more likely to be influenced by
the incidence of candidiasis in their unit, the risk of
increasing antifungal resist a n c ea n dt h ea b s e n c eo fa
statement by paediatric societies in support of routine
prophylaxis use than those who used prophylactic flucona-
zole (Table 2). Finally, neonatologists that did not prescribe
prophylaxis were more concerned about the need for
validated criteria to define high-risk neonates, including
surveillance cultures, although differences did not reach
significance.
Discussion
This is the first survey on the practices regarding antifungal
prophylaxis among level II and III NICUs from 28
European countries. Approximately half of the participating
neonatologists reported regular use of fluconazole prophy-
laxis in their NICUs. This survey gives evidence on how
widely prophylaxis administration modalities vary across
European NICUs and highlights three key factors influenc-
ing the prophylaxis decision process: the local incidence of
candidiasis, the potential risk of increasing antifungal
resistance and the need for additional efficacy trials.
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Indications for prophylaxis NICUs using fluconazole prophylaxis (n=99) Number of available data
n %
Birth gestational age No 25 27 93
<26 weeks 21 23
<28 weeks 30 32
<30 weeks 15 16
<32 weeks 2 2
Birth weight No 19 20 93
<750 g 14 15
<1,000 g 37 40
<1,500 g 22 24
Other (1,250 g) 1 1
Neonate receiving antibiotics for: No 38 41 92
>2 days 12 13
>7 days 25 27
>14 days 17 19
Presence of central venous catheter Yes 51 55 92
No 42 45
Positive colonization status Yes 50 52 96
No 46 48
Presence of endotracheal intubation Yes 23 25 92
No 69 75
Total parental nutrition in use Yes 35 38 92
No 57 62
Abdominal surgery Yes 23 26 90
No 67 74
Abdominal disease Yes 22 24 90
No 68 76
Table 2 Influence of nine factors in the decision whether or not to prescribe prophylactic fluconazole
Rationale for practice Use fluconazole
prophylaxis
(n=99), n (%)
Do not use prophylaxis
(n=86), n (%)
Number of
available data
p values
Likert≤3 Likert≥4 Likert≤3 Likert≥4
Incidence of candidiasis in your NICU is/is not
high enough to justify prophylaxis
55 (59) 39 (41) 17 (21) 64 (79) 181 <0.0001
Widespread antifungal use could lead to increased
antifungal resistance
48 (51) 46 (49) 25 (32) 54 (68) 178 0.01
Statement by paediatric societies in support of
routine use in a subset of newborns is needed
53 (60) 36 (40) 35 (44) 44 (56) 174 0.048
The criteria of high-risk patients in whom prophylaxis
should be attempted need clarification
40 (60) 27 (40) 37 (46) 44 (54) 179 0.23
The agent is too costly 89 (96) 4 (4) 74 (94) 5 (6) 178 0.73
The role of surveillance culture in identifying
high-risk neonates needs clarification
50 (55) 41 (45) 39 (48) 42 (52) 177 0.37
Uncertainty about pharmacometrics of the antifungal
agent in the newborn is great
62 (67) 31 (33) 48 (60) 32 (40) 178 0.36
Uncertainty about safety of the antifungal agent
in the newborn is great
67 (73) 25 (27) 53 (65) 28 (35) 178 0.29
Additional studies of efficacy of the antifungal agent
in the perinatal population are needed
41 (43) 54 (57) 29 (36) 52 (64) 181 0.32
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tion of IFIs in preterm neonates [7, 18]. In our survey, we
noticed variations among NICUs in the dosing schedule,
the frequency of administration and the duration of
fluconazole prophylaxis. Although usually administered
intravenously, several units still administer fluconazole or
other antifungal agents orally. Fluconazole has a good oral
absorption, but the action of other antifungal agents like
oral nystatin or miconazole is limited to the gastroenteric
tract, and their use is not supported by evidence from high-
level RCTs [2, 16]. Such diversity of practices with regard
to antifungal prophylaxis is in accordance with data from
previous surveys [5, 8] and highlights the need to establish
recommendations for fluconazole administration.
Furthermore, most participating neonatologists agreed
upon the need for additional efficacy data on prophylactic
fluconazole, as expressed in the 2004 US survey [5].
Nevertheless, the use of fluconazole is supported by high-
level evidence including five well-conducted RCTs that
enrolled a total of 656 neonates [6, 15, 17, 21, 24]. Meta-
analysis of these RCTs demonstrated that prophylactic
fluconazole significantly reduces the incidence of IFIs in
VLBW infants when compared to a placebo, with a number
of neonates needed to treat of 11 [7]. If neonatologists still
judge efficacy data as insufficient, then what is missing in
medical literature? First, no significant reduction on
mortality by prophylactic fluconazole has been demonstrated.
Long-term outcomes, such as disability-free survival,
have not been published. Both mortality and neuro-
developmental assessment may represent more adequate
trial endpoints to evaluate prophylactic medication
because they are direct consequences of IFIs and they
are not influenced by ascertainment bias as opposed to
the incidence of IFIs. However, these two outcomes in
preterm infants are multifactorial; thus, designing appropriate
trials to assess them is challenging. Second, as argued
by non-users of prophylaxis, neonates at high risk of
IFIs and the role of surveillance cultures need to be
defined. Although most clinicians agree to target the
youngest and smallest newborns, age and weight cut-
offs to initiate prophylaxis differ widely, and practices
are even more heterogeneous for other risk factors such
as antibiotic use and fungal colonization status. All
published RCTs were underpowered to perform subgroup
analysis, and the roleoffungalcolonization inthe progression
of the disease, although suggested [19], has never been
prospectively evaluated. This may partly explain why
paediatric societies have not issued recommendations on
antifungal prophylaxis in a targeted subset of neonates.
Also, most participating neonatologists agreed that
uncertainty about the pharmacometrics or safety of prophy-
lactic fluconazole does not influence their practices. Yet,
neonatal pharmacokinetic data of fluconazole to support
adequate dosing are limited and are totally missing in
neonates less than 750 g [28]. Likewise, prospective long-
term safety data, focusing on potential neurodevelopmental
impact, are missing in premature neonates.
The prevalence of fungal infections varies widely
between units because of differences in medical practices
like the management of central venous catheters or the use
of broad-spectrum antibiotics. In units where the rate of
infections is low (<1%), prophylactic fluconazole is not
necessary. However, a difference in infection rates between
NICUs using and those not using prophylaxis was not
evidenced in our survey. Also, the real incidence of IFIs in a
NICU remains difficult to determine because of the
frequent inability to yield the causal pathogen from cultures
in neonates and of the absence of a standardized definition
for IFIs [6, 13].
Moreover, clinicians who do not support antifungal
prophylaxis are more concerned about the potential risk
of increasing resistance as a consequence of its
widespread use. To date, several studies have addressed
this issue, and none has reported the emergence of
fluconazole-resistant Candida species [12, 15, 21]. Never-
theless, long-term mycological surveillance data are
currently not available. Overall, the findings of our survey
aresimilartothoseoftheUSsurvey[5], where neonatologists
who did not use fluconazole prophylaxis were also more
concerned about the emergence of resistance and the need to
further define high-risk neonates and evaluate the role of
surveillance cultures. However, information on the impact of
the local prevalence of fungal infections was not reported in
that article.
Due to the absence of an exhaustive list of NICUs and
the wide circulation of the survey's invitation, the total
number of units invited to participate is imprecise, and a
global response rate cannot be estimated. The above
reasons could also account for non-participation (survey
accessed online but questionnaire not completed) as part of
the contacted clinicians might not provide medical care for
very preterm and low birth weight neonates. In addition, the
number of questionnaires available from the different EU
countries varies, with Italy, the UK and France being
predominantly represented. This did not allow precise
geographic analysis of differences in fluconazole prophy-
lactic use between Northern and Southern Europe. Never-
theless, the main objective of the survey was not to quantify
the frequency of use of fluconazole prophylaxis and to
extrapolate it at a global European level. Finally, we did not
question all practising neonatologists in each NICU, and we
did not test the respondents' knowledge of the current
literature. However, questionnaires were completed by the
heads of NICUs, whose opinion is frequently reflective of
the practices in a unit and whose status may be a proxy for
literature knowledge.
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Use and dosage schedule of routine fluconazole prophy-
laxis are currently variable among European NICUs.
Responders acknowledged the need for additional trials to
evaluate the efficacy of prophylactic fluconazole regardless
of their respective practice of prophylaxis. Nevertheless,
neonatologists who did not use fluconazole prophylaxis
were more likely to be influenced by the local incidence of
candidiasis, the risk of emergence of antifungal resistances
and the absence of a statement by paediatric societies to
support routine use of prophylaxis. Future studies that will
address these issues will contribute to a more rational and
safer use of antifungal fluconazole prophylaxis.
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